VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023
STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) to Complete Enrollment this Quarter
Related news for (VECT)
- VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
- VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
- VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)